Meeder Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Meeder Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.8K	Buy	122 +81	+198%	+$4.27K	﹤0.01%	801
2025 Q4	$2.15K	Sell	41 -5	-11%	-$299	﹤0.01%	865
2025 Q3	$2.98K	Buy	+46	New	+$2.64K	﹤0.01%	746
2021 Q2	–	Sell	-46	Closed	-$6K	–	2530
2021 Q1	$6K	Buy	+46	New	+$6.95K	﹤0.01%	1781
2020 Q2	–	Sell	-12	Closed	-$1K	–	2125
2020 Q1	$1K	Hold	12	–	–	﹤0.01%	2172
2019 Q4	$1K	Buy	+12	New	+$655	﹤0.01%	2124

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meeder Asset Management's CRSP Position: Q1 2026 in Review

Meeder Asset Management increased its CRISPR Therapeutics (CRSP) stake by 198% in Q1 2026, buying an estimated $4.27K and bringing the position to 122 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #801.

Meeder Asset Management first reported a position in CRSP in Q4 2019 and has held it in 6 quarters since. The position peaked at $6K in Q1 2021. 489 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Meeder Asset Management held 122 shares of CRISPR Therapeutics worth $5.8K as of Q1 2026.
Meeder Asset Management bought 81 CRISPR Therapeutics shares in Q1 2026, an estimated $4.27K.
CRISPR Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #801 holding.
Meeder Asset Management first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 6 quarters since.
Meeder Asset Management's CRISPR Therapeutics position peaked at $6K in Q1 2021.
489 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.